GlassScriptPhysician profile
Tara D Morris
NPI 1861547531
$6,147.43
in general payments reported to CMS, 2019-2025
29 companies · $1,356 in 2025
The $1,356 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.65 · 2020: $165 · 2021: $781 · 2022: $914 · 2023: $1,311 · 2024: $1,576 · 2025: $1,356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,988 · Education: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,987.53 |
| Education | $255.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,187.95 | 2020-2024 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $796.12 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $505.34 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $450.08 | 2021-2025 | Bimzelx |
| Leo Pharma INC. | $387.11 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $328.47 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $323.97 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $244.36 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $234.90 | 2021-2025 | Ilumya, Blu-U |
| Regeneron Healthcare Solutions, INC. | $228.85 | 2021-2025 | Dupixent, Libtayo |
| Pfizer INC. | $210.78 | 2022-2025 | |
| Incyte Corporation | $197.13 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $171.44 | 2024-2025 | Aklief |
| Merz North America, INC. | $122.98 | 2021-2023 | Xeomin |
| Amgen INC. | $121.77 | 2021-2025 | Otezla, Otezla |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $114.80 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $91.42 | 2021-2025 | Cabtreo |
| Botanix Sb INC | $83.63 | 2025 | Sofdra |
| Blueprint Medicines Corporation | $77.86 | 2024-2025 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.68 | 2024-2025 | Spevigo |
| Dermavant Sciences, INC. | $37.47 | 2022-2023 | Vtama |
| Genentech USA, INC. | $29.53 | 2021 | |
| Almirall LLC | $26.98 | 2022 | |
| Vyne Pharmaceuticals INC. | $24.86 | 2020 | |
| Lnhc, INC | $24.76 | 2025 | Zelsuvmi |
| Celgene Corporation | $20.01 | 2019 | |
| Epi Health, LLC | $17.25 | 2021 | |
| Revance Therapeutics, INC. | $15.75 | 2025 | Daxxify |
| Biofrontera INC. | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.